Australia's Therapeutic Goods Administration (TGA) issued a warning on 6 November 2026 about Synedica injectable products after testing found they did not contain what their labels claimed. The Herald Sun reported the finding the same day.

Which products were tested?

Three products : Synedica BPC 157 & TB 500 10 mg, Synedica KLOW 80 mg and Synedica BARBIE KLOW 100 mg : contained no detectable TB-500 despite claiming to. Products also labelled as containing retatrutide, an unapproved GLP-1 drug still in clinical trials, held less than the stated 10 mg. The amount varied significantly between individual pens tested.

What risk did the TGA identify?

TGA chief medical adviser Professor Robyn Langham said: uncertain contents and the possibility of severe allergic reactions were central concerns.

TGA head Chris Bedford called the growing unlawful supply and promotion of unapproved peptides "a serious concern" and said the regulator would work with law enforcement to disrupt it. The products were seized in a NSW police operation.

Why is this relevant in the UK?

The UK's MHRA has investigated peptide clinics and raided premises in Birmingham for similar products. The ASA Pulse Report rated no sampled research peptide ad as low compliance risk. The TGA finding adds evidence that unlabelled injectable products carry unknown contents and risk.

Scope for European readers

This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.